Richmond Pharmacology enhances its established GE MUSE platform with the State-of-the-art Mortara 12-lead telemetry setup

Posted:
8
November 2011

Richmond Pharmacology enhances its established GE MUSE platform with theState-of-the-art Mortara 12-lead telemetry setupEnhancing our well tested GE MUSE platform, Richmond Pharmacology today added the state-of-the-art Mortara 12-lead telemetry setup providing the most comprehensive TQT measurement platform available.Key features include:

  • 12-lead Telemetry Monitoring

With the Mortara X12+  and T12S  transmitters, the Surveyor  Telemetry Central System enables continuous 12-lead monitoring and trending for thorough evaluation of ECG intervals, ST segment change, and arrhythmias using VERITAS  ECG algorithms.

  • 12-lead ECG On-Demand

Continuous 12-lead monitoring enables diagnostic 12-lead ECG acquisition on-demand without any additional device or patient hookup.  12-lead ECGs with VERITAS measurements and interpretation can be printed and exported to an E-Scribe� data management system either manually or automatically.This is an alternative to our established GE GETEMED 12-lead Holter platform.At Richmond Pharmacology we are so confident that we can deliver a successful TQT study we ensure a fixed price guarantee. Furthermore our confidence in our experience means that should we fail to show Thorough QT assay sensitivity we will repeat your study at no cost to you.Contact a member of our Business Development team now to discuss your prospective QT study requirements.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more